Rhinitis - Pipeline Insight, 2025

DelveInsight’s, “Rhinitis - Pipeline Insight, 2025,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Rhinitis Understanding

Rhinitis: Overview

Rhinitis is a condition that typically involves nasal obstruction or congestion, runny nose or post-nasal drip, itchy nose, and/or sneezing. There are various causes for these symptoms, although they are broadly divided into two types: allergic rhinitis (nasal symptoms related to allergy) and non-allergic rhinitis (nasal symptoms that are not related to allergy). Rhinitis may occur before a case of sinusitis or with sinusitis, a condition where infection or inflammation affects the sinuses. If you have facial pressure, decreased sense of smell, or a greenish-yellow nasal drainage, you may also have sinusitis. A qualified ENT (ear, nose, and throat) specialist, or otolaryngologist, can provide a thorough evaluation and appropriate treatment for your nasal/sinus condition. Allergic rhinitis, also known as hay fever, occurs when your body’s immune system over-responds to specific, non-infectious particles such as plant pollens, molds, dust mites, animal proteins, chemicals, foods, medicines, insect venom, and other triggers. During an allergic attack, a special antibody (fighting protein), called IgE, attaches to cells that release histamine and other chemicals in the lungs, skin, and the mucous linings of the body. These chemicals open the blood vessels and produce skin redness and swollen membranes. When this happens in the nose, sneezing, itching, runny nose, and congestion occur. Treating rhinitis depends on the specific cause or diagnosis. If there is a specific trigger that can be avoided, this may be a successful treatment. For example, in people with cat allergy, avoidance of cat exposure and direct contact with cats may help to control symptoms. For allergic rhinitis, allergen immunotherapy may be an option. This is most commonly provided via allergy shots or tablets or liquid drops taken under the tongue.

""Rhinitis - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rhinitis pipeline landscape is provided which includes the disease overview and Rhinitis treatment guidelines. The assessment part of the report embraces, in depth Rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Rhinitis.
• In the coming years, the Rhinitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Rhinitis treatment market. Several potential therapies for Rhinitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Rhinitis market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Rhinitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Rhinitis Emerging Drugs Chapters

This segment of the Rhinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rhinitis Emerging Drugs

• REGN1908-1909: Regeneron

REGN1908-1909 is a novel cocktail of two fully-human monoclonal IgG antibodies, designed to specifically bind and block the Fel d 1 allergen, thus preventing it from binding and triggering the endogenous antibodies that cause allergies (i.e., Immunoglobulin E, or IgE, antibodies). REGN1908-1909 was invented using Regeneron's proprietary VelocImmune® technology. Currently, it is in phase III stage of clinical trial evaluation to treat Allergic Rhinitis Due to Cat Allergy.

• IRL201104: Revolo Biotherapeutics

IRL201104 was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It is expected to provide long-term remission for many allergic diseases. IRL201104 has been shown to quickly and markedly reduce lung infiltration of neutrophils in mice following bronchial challenge with lipopolysaccharide stimulating acute neutrophil activation. IRL1104 has a very short circulation exposure following IV administration and acts on neutrophil infiltration quickly but in a transient manner, which may mean that it would be able to provide a marked, but temporary, reduction in lung neutrophilia, potentially allowing the lung some respite from the high level of inflammation. Currently, it is in phase II stage of clinical trial evaluation to treat Seasonal Allergic Rhinitis.

Further product details are provided in the report……..

Rhinitis: Therapeutic Assessment

This segment of the report provides insights about the different Rhinitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Rhinitis

There are approx. 35+ key companies which are developing the therapies for Rhinitis. The companies which have their Rhinitis drug candidates in the most advanced stage, i.e. phase III include, Regeneron.

• Phases

DelveInsight’s report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rhinitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rhinitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rhinitis drugs.

Rhinitis Report Insights

• Rhinitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Rhinitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Rhinitis drugs?
• How many Rhinitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rhinitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rhinitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rhinitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Regeneron
• Revolo Biotherapeutics
• Anhui Palo Alto Pharmaceuticals, Inc.
• Abdi Ibrahim Pharmaceuticals
• Lyra Therapeutics
• Inmunotek
• Iltoo Pharma
• Advagene Biopharma Co. Ltd.
• AOBiome LLC
• Sanofi
• Hanmi Pharmaceutical Company Limited
• Emergo Therapeutics
• Inimmune
• Paradigm Biopharmaceuticals
• Dong Wha PHARM.CO.,LTD
• Siolta Therapeutics
• Revelation Biosciences Inc.
• Allergy Therapeutics
• NeuCen BioMed
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Biomay AG

Key Products

• REGN1908-1909
• IRL201104
• PA9159
• AI201901
• LYR-210
• REGN 5713 5714 5715
• CSPCHA115
• MM09
• CEN501
• MG 01/T 517
• Grass MATA MPL
• REVTx-99b
• ILT-101
• AD17002
• B244
• DW2008
• Dupilumab
• INI-2004
• HCP1102
• Norketotifen
• STMC-103H
• BM41